SCHEMBL20614930

SCHEMBL20614930

CCOC(=O)c1cc2c(s1)-c1cnccc1NCC2

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.57
KDM4E B2RXH2 4/20 0.57
HPGD P15428 3/20 0.57
TDP1 Q9NUW8 3/20 0.57
L3MBTL1 Q9Y468 3/20 0.57
MAPK14 Q16539 1/20 0.47
CDC7 O00311 3/20 0.43
DBF4 Q9UBU7 3/20 0.43
GAA P10253 3/20 0.41
MAPT P10636 3/20 0.41
GLA P06280 2/20 0.41
RAB9A P51151 2/20 0.41
ATM Q13315 2/20 0.41
NPC1 O15118 1/20 0.41
JAK2 O60674 2/20 0.38
JAK3 P52333 2/20 0.38
TP53 P04637 1/20 0.37
CYP2C9 P11712 1/20 0.36
ALOX15 P16050 1/20 0.36
CYP2C19 P33261 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20614680 0.91 ALDH1A1 (0.57) ALDH1A1KDM4EHPGDTDP1L3MBTL1
SCHEMBL11910402 0.85 KDM4E (0.70) ALDH1A1KDM4EHPGDTDP1L3MBTL1
Bromide SCHEMBL19689589 0.84 KDM4E (0.69) ALDH1A1KDM4EHPGDTDP1L3MBTL1
Hydrochloric Acid SCHEMBL19689605 0.84 KDM4E (0.69) ALDH1A1KDM4EHPGDTDP1L3MBTL1
SCHEMBL12797278 0.83 KDM4E (0.63) ALDH1A1KDM4EHPGDTDP1L3MBTL1
SCHEMBL20619601 0.80 KDM4E (0.57) ALDH1A1KDM4EHPGDTDP1L3MBTL1
SCHEMBL20599149 0.80 KDM4E (0.57) ALDH1A1KDM4EHPGDTDP1L3MBTL1
SCHEMBL20614931 0.79 KDM4E (0.55) ALDH1A1KDM4EHPGDTDP1L3MBTL1
SCHEMBL19454421 0.79 ALDH1A1 (0.54) ALDH1A1KDM4EHPGDTDP1L3MBTL1
SCHEMBL20614760 0.78 ALDH1A1 (0.54) ALDH1A1KDM4EHPGDTDP1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10851115-B2 Heterocyclic compounds as RSV inhibitors ENANTA PHARMACEUTICALS, INC. (US) 2020-12-01 US disclosed
WO-2019006291-A1 HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS ENANTA PHARMACEUTICALS, INC. (US) 2019-01-03 WO disclosed
US-20190002478-A1 HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS ENANTA PHARMACEUTICALS, INC. 2019-01-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190002478-A1 HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS SIRT1, FURIN, SIRT5 ALDH1A1 721/4885KDM4E 1342/4885HPGD 157/4885
US-10851115-B2 Heterocyclic compounds as RSV inhibitors SIRT1, FURIN, SIRT5 ALDH1A1 721/4885KDM4E 1342/4885HPGD 157/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.